Communiqués Serina Therapeutics, Inc.

Actions

SER

US81751A1088

Recherche biotechnologique et médicale

Marché Fermé - NYSE Autres places de cotation 22:00:00 30/07/2026			Varia. 5j.	Varia. 1 janv.
2,040 ^USD	-1,45%		-2,39%	+6,64%

23/07	Serina achève le recrutement et l'administration des doses pour la première cohorte de son essai de phase 1b dans la maladie de Parkinson	MT
22/07	Serina Therapeutics, Inc. annonce la nomination de Farrell Simon au conseil d'administration et à ses comités, avec effet au 22 juillet 2026	CI

Communiqués

24/07	Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference	AQ
23/07	Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson’s Disease	AQ
22/07	Serina Therapeutics Appoints Farrell Simon to its Board of Directors	AQ
09/07	Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease	AQ
30/06	Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program	AQ
22/05	Serina Therapeutics : Enable Injections Announces CE Certification of the enFuse® On-Body Delivery System for Use with Aspaveli® Distributed by Sobi	PU
14/05	Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates	AQ
07/04	Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit	AQ
02/04	Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan	AQ
25/03	Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights	AQ
24/03	Serina Therapeutics to Present at the 38th Annual Roth Conference	AQ
18/03	Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson’s Disease	AQ
24/02	Serina Therapeutics : Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease	PU
19/02	Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease	AQ
03/02	Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event	AQ
30/01	Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson's disease	AQ
29/01	Serina Therapeutics : Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson’s disease	PU
16/01	Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders Equity	AQ
15/01	Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity	AQ
06/01	Serina Therapeutics : Enable Injections Announces $30 Million Investment from Sanofi to Accelerate Manufacturing Capabilities	PU
18/12	Serina Therapeutics : Enable Injections Announces Regulatory Approval in Saudi Arabia for the EMPAVELI® Injector based on enFuse® Technology	PU
11/12	Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry	AQ
10/12	Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program	AQ
13/11	Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights	AQ
03/11	Serina Therapeutics Provides Regulatory Update on SER-252 Program	AQ